A Prospective Randomized Rater-Blinded 6-Month Head-To-Head Trial to Evaluate the Safety and Tolerability of Paliperidone ER Versus Olanzapine in Patients With Schizophrenia.

Trial Profile

A Prospective Randomized Rater-Blinded 6-Month Head-To-Head Trial to Evaluate the Safety and Tolerability of Paliperidone ER Versus Olanzapine in Patients With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Paliperidone (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 19 Jun 2012 Results published in the Journal of Clinical Psychopharmacology.
    • 14 Sep 2010 US FDA approved NDA for paliperidone for the acute and maintenance treatment of schizophrenia based data from this and other pivotal trials.
    • 01 Sep 2010 Primary endpoint results (n=459) presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top